- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04478578
Forekomster, årsaker og utfall av febersykdom i landlige Sør- og Sørøst-Asia (SEACTN-WP-A)
Bestemmelse av forekomst, årsaker og utfall av rural febersykdom (RFI) i Sør- og Sørøst-Asia, som en del av Sør- og Sørøst-asiatiske fellesskapsbaserte prøvenettverk (SEACTN). Arbeidspakke A (WP-A).
The study will collect information to understand the causes and outcomes of febrile illness in rural areas in countries across South and Southeast Asia (including Cambodia, Laos, Myanmar and Bangladesh). The findings will be used to identify new tests and treatments that can improve the management of febrile patients in the future.
This study is funded by the UK Wellcome Trust. The grant reference number is 215604/Z/19/Z
Studieoversikt
Status
Forhold
Detaljert beskrivelse
This study aims to better understand and quantify the burden of febrile illness, the aetiological causes and the manner in which it affects the people living in rural areas in South and Southeast Asia, all on a scale which has not been attempted before. The SEACTN RFI project will collect information to help better understand and predict these outcomes based on a multitude of factors, which will form the basis for interventions within the network in the future. Determining the incidence, causes and outcomes of febrile illness in these settings will be done through two work packages. The first of these, Work Package A (WP-A), the subject of this study, will be carried out at the community level, primarily by engaging village health worker (VHWs) and low-level Health Centres (HCs) which serve the communities to recruit patients presenting with a febrile illness. These patients will be assessed for presenting symptoms and followed up for clinical outcomes. Collection of specimen for diagnostic investigations in these settings is challenging. Currently, mRDTs are conducted by VHWs and HCs in these networks, therefore by using the same process, but also applying blood to filter paper and allowing it to dry (DBS), investigators will test for certain other pathogens, which will increase the aetiological yield.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Dhaka, Bangladesh, 1212
- Building Resources Across Communities (BRAC)
-
-
-
-
-
Yangon, Burma, 11201
- Medical Action Myanmar (MAM)
-
-
-
-
-
Battambang, Kambodsja
- Action for Health Development (AHEAD)
-
-
-
-
Vientiane Prefecture
-
Vientiane, Vientiane Prefecture, Laos, 01000
- Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU)
-
-
-
-
-
Chiang Rai, Thailand, 57000
- Chiangrai Clinical Research Unit (CCRU)
-
-
Bangkok
-
Ratchathewi, Bangkok, Thailand, 10400
- Mahidol VivaResearch Unit, Faculty of Tropical Medicine, Mahidol University (MVRU)
-
-
Changwat Tak
-
Mae Sot, Changwat Tak, Thailand, 63110
- Shoklo Malaria Research Unit (SMRU)
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Patients with an acute febrile illness of all ages presenting to village health workers (VHWs) or peripheral health facilities.
Beskrivelse
Inclusion Criteria:
- Documented fever (≥ 37.5°C axillary), hypothermia (< 35.5°C) and/or history of fever in the last 24 hours.
- Willingness and ability to comply with study protocol for the study duration.
- Written informed consent given to participate in the trial.
Exclusion Criteria:
- Currently enrolled in the study
- Accident or trauma is the cause for presentation
- Presentation ≤ 3 days after routine immunisations
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: CASE_ONLY
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Patients with febrile illness
Participants from approximately 650 villages, with a target number of 100,000 episodes of febrile illness, will be enrolled into this study. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Local incidence of febrile illness
Tidsramme: From Months 0 to 24
|
The incidence per year that an individual seeks care for a febrile illness with the village health workers or local health facility, at the village level. |
From Months 0 to 24
|
|
Overall incidence of febrile illness
Tidsramme: From Months 0 to 24
|
The incidence per year that an individual seeks care for a febrile illness with the village health workers or local health facility, at the regional level. These estimates will later be triangulated with and extrapolated from using health seeking behavior surveys for an estimate of the total incidence of febrile illness. |
From Months 0 to 24
|
|
Mortality
Tidsramme: Within approximately 1 month of first presentation to the village health worker or health facility
|
Case fatality rates in febrile illness |
Within approximately 1 month of first presentation to the village health worker or health facility
|
|
Morbidity
Tidsramme: Over 1 month after first presentation
|
Duration of illness in patients presenting with a fever to the village health worker or health facility. |
Over 1 month after first presentation
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Prevalence of pathogens in febrile patients
Tidsramme: Samples collected over approximately 24 months
|
Pathogens will be detected in patients presenting over a 24 month period using point of care tests and diagnostic assays on acute and convalescent dried blood spots. |
Samples collected over approximately 24 months
|
|
The correlation between host biomarker concentrations, aetiological diagnoses and clinical outcomes.
Tidsramme: Samples collected over approximately 24 months
|
The area under the curve, sensitivity and specificity of host biomarkers to identify bacterial infections and to predict severe outcomes. |
Samples collected over approximately 24 months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Yoel Lubell, Prof, Mahidol Oxford Tropical Medicine Research Unit
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- BAC20001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Data collected for this study will be under the custodianship of MORU. With participant's consent, data from this study may be shared in a de-identified form with other groups or researchers in accordance with the MORU Data Sharing Policy.
IPD-delingstidsramme
After completion of trial activities and reporting
Tilgangskriterier for IPD-deling
MORU Data Sharing Policy. (http://www.tropmedres.ac/data-sharing-policy)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .